GAITHERSBURG, Md., Oct. 23 /PRNewswire/ -- MedImmune today announced that researchers will present eight posters from its inflammatory disease program at the Annual Meeting of the American College of Rheumatology, from October 24 to 29, 2008 at the Moscone Center in San Francisco, California.
"MedImmune is working on a number of potential solutions for patients struggling with systemic autoimmune rheumatic diseases," said Barbara White, M.D., vice president, clinical development, respiratory, inflammation, and autoimmunity. "We are pleased to share promising basic research and translational science data relevant to the development of new treatments for diseases such as lupus, rheumatoid arthritis, and myositis"
MedImmune programs that will be discussed include:
MedImmune has a preclinical program investigating antibodies that target CXCL13 which may have the potential to prevent the generation of these inflammatory follicles within the rheumatic joint.
About MedImmune
MedImmune is a leading innovation-focused biotechnology company whose mission is to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/ gastrointestinal disease and neuroscience. Headquartered in Gaithersburg, Maryland, MedImmune has approximately 3,000 employees worldwide and is the wholly owned biologics business for AstraZeneca plc . For more information, visit MedImmune's website at www.medimmune.com.
CONTACT: Media: Sidoney Atse, +1-301-398-5990, or Investors: Peter Vozzo,
+1-301-398-4358, both of MedImmune
Web site: http://www.medimmune.com/
